Eric Murphy

Sidewinder Therapeutics is a San Diego, CA based biotechnology company pioneering the next generation of large molecule precision therapeutics. We aim to deliver new life saving therapies for cancer and rare disease patients.

Sidewinder Therapeutics is a San Diego, CA based biotechnology company pioneering the next generation of large molecule precision therapeutics. We aim to deliver new life saving therapies for cancer and rare disease patients.

Alterome Therapeutics, Inc. is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. We are a team with expertise in multiple areas of science and operations, dedicated to co-elevating toward our vision to bring life-changing and life-saving therapies to cancer patients. We believe in our journey, in each other, and in our ability to collaboratively develop therapies that will help end cancers. Thus, we seek the best people for our company and provide the resources they need to grow, develop, and accomplish our collective goals. We are moving forward with humility & empathy, fearlessness & resilience, with a sense of inclusion & belonging, open communication and a deep trust. And…we manage to have a lot of fun along the way!

Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs and to overcome the limitations, such as non-responsiveness or acquired and intrinsic resistance. Kinnate has two clinical programs being studied in solid tumors with RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a pipeline of additional small molecule drug candidates as part of the Kinnate Discovery Engine. The company is driven by the urgency and knowledge that patients are waiting for new, effective cancer medicines.

The Genomics Institute of the Novartis Research Foundation (GNF), founded in 1999 and now with over 560 employees, is under the umbrella of the Novartis Institute for Biomedical Research (NIBR) and is affiliated with the Novartis Institute for Developing World Medical Research (NIDWMR). GNF applies integrated state-of-the-art technologies in chemistry, biology, automation, and information sciences in order to pursue new approaches towards the understanding of complex biomedical problems in cancer biology, immunology, neuroscience, and metabolic as well as infectious disease. These technologies cut across the life sciences, and include genomics and proteomics tools, medicinal chemistry, cell-based high throughput screening of genes or compounds, structural genomics, and forward/reverse mammalian genetics.